HI-Bio: A Biogen Company (@hibiosciences) 's Twitter Profile
HI-Bio: A Biogen Company

@hibiosciences

HI-Bio has been acquired by @Biogen. Please follow along there for the latest news. This page is no longer updated or monitored.

ID: 1519049628196519941

linkhttps://hibio.com calendar_today26-04-2022 20:24:07

43 Tweet

49 Followers

37 Following

HI-Bio: A Biogen Company (@hibiosciences) 's Twitter Profile Photo

We are excited to announce that the FDA has granted Breakthrough Therapy designation for felzartamab for primary membranous nephropathy! Learn more about this important step forward: hibio.com/news/hi-bio-an…

We are excited to announce that the FDA has granted Breakthrough Therapy designation for felzartamab for primary membranous nephropathy! Learn more about this important step forward: hibio.com/news/hi-bio-an…
HI-Bio: A Biogen Company (@hibiosciences) 's Twitter Profile Photo

We enjoyed attending American Society of Nephrology’s annual Kidney Week meeting, where we presented final Phase 2 M-PLACE data. Thanks to our collaborators, advisors and everyone who made the event possible. You can read our posters and presentations from the meeting here: hibio.com/science#public…

We enjoyed attending <a href="/ASNKidney/">American Society of Nephrology</a>’s annual Kidney Week meeting, where we presented final Phase 2 M-PLACE data. Thanks to our collaborators, advisors and everyone who made the event possible. You can read our posters and presentations from the meeting here: hibio.com/science#public…
HI-Bio: A Biogen Company (@hibiosciences) 's Twitter Profile Photo

Today, we’re pleased to announce our $95 million Series B to advance targeted therapies for immune-mediated diseases – bringing felzartamab, our clinically differentiated lead candidate, through clinical readouts and preparation for registrational studies. hibio.com/news/hi-bio-an…

Today, we’re pleased to announce our $95 million Series B to advance targeted therapies for immune-mediated diseases – bringing felzartamab, our clinically differentiated lead candidate, through clinical readouts and preparation for registrational studies. hibio.com/news/hi-bio-an…
HI-Bio: A Biogen Company (@hibiosciences) 's Twitter Profile Photo

We are excited to announce that the FDA has granted orphan drug designation for felzartamab, our investigational agent in development for the treatment of antibody-mediated rejection in kidney transplant recipients! More on this important step here: hibio.com/news/hi-bio-re…

We are excited to announce that the FDA has granted orphan drug designation for felzartamab, our investigational agent in development for the treatment of antibody-mediated rejection in kidney transplant recipients! More on this important step here: hibio.com/news/hi-bio-re…
HI-Bio: A Biogen Company (@hibiosciences) 's Twitter Profile Photo

Today is IgAN Awareness Day! IgAN is a serious, rare kidney disease, impacting more than 130,000 patients in the U.S. today. We're proud to work with investigators to advance therapies for patients in need. Thanks to the @IgANFoundation for their work! #IgANAware

HI-Bio: A Biogen Company (@hibiosciences) 's Twitter Profile Photo

Today we announced a definitive agreement under which Biogen has agreed to acquire HI-Bio. The proposed acquisition combines expertise in immune-mediated indications with global development and commercial experience in rare diseases. Read more: hibio.com/news/biogen-bo…

Today we announced a definitive agreement under which <a href="/biogen/">Biogen</a> has agreed to acquire HI-Bio. The proposed acquisition combines expertise in immune-mediated indications with global development and commercial experience in rare diseases. 

Read more: hibio.com/news/biogen-bo…
HI-Bio: A Biogen Company (@hibiosciences) 's Twitter Profile Photo

This weekend, our team attended the AmericanTransplantCongress to further discuss the recent positive felzartamab data in antibody-mediated rejection (AMR) in kidney transplant recipients recently featured in NEJM. View the presentation here: assets.hibio.com/undefined/fina… #ATC2024Philly

This weekend, our team attended the <a href="/ATCMeeting/">AmericanTransplantCongress</a> to further discuss the recent positive felzartamab data in antibody-mediated rejection (AMR) in kidney transplant recipients recently featured in <a href="/NEJM/">NEJM</a>. View the presentation here: assets.hibio.com/undefined/fina…

#ATC2024Philly
HI-Bio: A Biogen Company (@hibiosciences) 's Twitter Profile Photo

The acquisition of HI-Bio by Biogen has been completed. Together, we will be advancing our clinical development plans to deliver innovative treatments to patients in need. Follow @Biogen for the latest news and read about the acquisition: investors.biogen.com/news-releases/…

The acquisition of HI-Bio by Biogen has been completed. Together, we will be advancing our clinical development plans to deliver innovative treatments to patients in need. Follow @Biogen for the latest news and read about the acquisition: investors.biogen.com/news-releases/…